CRPC
Metastatic castration-resistant prostate cancer
Advertisement
Dr. Kimura shares insights on PSMA PET/CT metrics and their potential role in guiding treatment decisions for mCRPC.
Quantitative analysis outperformed visual analysis in the prediction of outcomes for patients undergoing Lu-PSMA therapy.
New research explores the prognostic potential of LuPSMA-SPECT/CT with RECIP 1.0 in patients with advanced prostate cancer.
Dr. Tagawa explains the rationale for EVOLUTION, a phase II analysis of Lu-PSMA-617 with ipilimumab and nivolumab in mCRPC.
Dr. Tagawa contextualizes a post hoc analysis on clonal hematopoiesis in those who received 177Lu-PSMA-617 or cabazitaxel.
Dr. Tagawa showcases the ProstACT Global trial, a phase III study of 177Lu-rosptamab in patients with mCRPC.
Dr. Tagawa breaks down the VIOLET study, a single-arm phase I/II first-in-human results of terbium-161Tb-PSMA-I&T.
Dr. Ozay discusses her study that compared the efficacy of cabazitaxel with lutetium Lu-177 in patients with mCRPC.
Louise Emmett, MD, discusses the ENZA-p trial which studied enzalutamide versus enzalutamide plus [177Lu] Lu-PSMA-617.
Researchers studied clonal hematopoiesis mutations in patients treated with 177Lu-PSMA-617 or cabazitaxel for prostate cancer
The addition of ipi/nivo to LuPSMA improved PSA-PFS over 12 months in patients with mCRPC.
18F-flotufolastat-PET can help determine severe hematologic toxicity in patients with mCRPC who are treated with 177Lu.
Radium 223 is recommended for patients with symptomatic bone-only disease.
177Lu vipivotide tetraxetan is the only PSMA-targeted agent to significantly improve rPFS with a tolerable safety profile.
Enzalutamide with [177Lu]Lu-PSMA-617 improved OS and HRQOL, along with PSA PFS.
Dr. Tan discusses the TALAPRO-2 study, PARP inhibitor synergy, HRR testing, and evolving treatment strategies in mCRPC.
The combination demonstrated a manageable safety profile with evidence of EZH2 pharmacodynamic inhibition and OR.
Final TALAPRO-2 results show talazoparib + enzalutamide significantly improves survival in patients with HRR-deficient mCRPC.
New research sheds light on the real-world outcomes of Lu-PSMA-617 in a racially diverse patient population.
Tala/enza demonstrated improvement in OS compared with enza alone as 1L treatment in patients with mCRPC.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.